Loading...
XKRX
200670
Market cap295mUSD
Dec 05, Last price  
43,950.00KRW
1D
-0.68%
1Q
-29.57%
Jan 2017
47.18%
IPO
51.74%
Name

Humedix Co Ltd

Chart & Performance

D1W1MN
XKRX:200670 chart
P/E
11.10
P/S
2.69
EPS
3,959.15
Div Yield, %
1.19%
Shrs. gr., 5y
1.53%
Rev. gr., 5y
15.54%
Revenues
161.87b
+6.30%
42,133,25047,133,616,79254,727,015,69264,831,668,74478,618,778,77298,480,868,087110,992,354,033123,172,789,865152,273,808,567161,872,958,000
Net income
39.26b
+58.17%
11,622,59710,274,737,72811,940,469,3099,207,790,76010,420,174,41615,084,078,5909,064,623,50021,086,065,77024,820,704,79039,259,415,000
CFO
50.74b
+64.30%
11,706,2157,609,285,0048,765,496,46023,802,879,23913,809,722,49423,762,116,51819,184,529,55238,152,026,54530,885,207,98050,744,191,000
Dividend
Jun 27, 2024250 KRW/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Humedix Co., Ltd., a healthcare company, researches, develops, manufactures, and sells various pharmaceutical products in South Korea. It offers over-the-counter drugs, prescription medicines, active pharmaceutical ingredients, medical devices, cosmetic products, and functional synthetic materials, as well as health functional foods. The company was formerly known as HVLS Co., Ltd. and changed its name to Humedix Co., Ltd. in 2010. The company was founded in 2002 and is headquartered in Anyang-si, South Korea.
IPO date
Dec 26, 2014
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT